LU92976I2 - Asfotase alfa - Google Patents

Asfotase alfa Download PDF

Info

Publication number
LU92976I2
LU92976I2 LU92976C LU92976C LU92976I2 LU 92976 I2 LU92976 I2 LU 92976I2 LU 92976 C LU92976 C LU 92976C LU 92976 C LU92976 C LU 92976C LU 92976 I2 LU92976 I2 LU 92976I2
Authority
LU
Luxembourg
Prior art keywords
amino acid
absent
acid sequence
asfotase alfa
salp
Prior art date
Application number
LU92976C
Other languages
English (en)
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of LU92976I2 publication Critical patent/LU92976I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LU92976C 2007-05-11 2016-02-10 Asfotase alfa LU92976I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (fr) 2007-05-11 2008-05-12 Phosphatase alcaline ciblant les os, trousses et procédés pour son utilisation

Publications (1)

Publication Number Publication Date
LU92976I2 true LU92976I2 (en) 2016-04-11

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92976C LU92976I2 (en) 2007-05-11 2016-02-10 Asfotase alfa

Country Status (25)

Country Link
US (1) US20100297119A1 (fr)
EP (3) EP2662448B1 (fr)
JP (1) JP5732603B2 (fr)
AT (1) ATE536413T1 (fr)
AU (1) AU2008250945B2 (fr)
BR (2) BRPI0811198B8 (fr)
CA (1) CA2687001C (fr)
CY (1) CY2016005I1 (fr)
DE (1) DE202008018131U1 (fr)
DK (3) DK2662448T3 (fr)
ES (3) ES2380546T3 (fr)
HK (3) HK1141047A1 (fr)
HR (1) HRP20140416T1 (fr)
HU (2) HUE031655T2 (fr)
IL (1) IL202057A0 (fr)
LT (1) LTC2368999I2 (fr)
LU (1) LU92976I2 (fr)
ME (1) ME01828B (fr)
NL (1) NL300798I1 (fr)
NO (1) NO2016002I2 (fr)
PL (3) PL2662448T3 (fr)
PT (3) PT2662448T (fr)
RS (1) RS53302B (fr)
SI (2) SI2662448T1 (fr)
WO (1) WO2008138131A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1759001B1 (fr) 2004-04-21 2011-04-13 Enobia Pharma Inc. Conjugues de delivrance dans l'os et procede d'utilisation pour le ciblage de proteines vers l'os
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
CN101835802B (zh) 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
WO2011113027A2 (fr) 2010-03-12 2011-09-15 Synageva Biopharma Corp Protéines de fusion npp1
CA2797865A1 (fr) * 2010-04-30 2011-11-03 Alexion Pharma International Sarl Procedes, compositions et trousses pour le traitement de troubles de la mineralisation de la matrice
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
CA2823066A1 (fr) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions contenant des peptides natriuretiques et leurs methodes d'utilisation
CA2852874A1 (fr) * 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprenant une phosphatase alcaline et/ou un peptide natriuretique et leurs procedes d'utilisation
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
JP6940949B2 (ja) * 2014-01-24 2021-09-29 アーエム−ファルマ ベー．フェー．ＡＭ−Ｐｈａｒｍａ Ｂ．Ｖ． キメラアルカリホスファターゼ様タンパク質
US10822596B2 (en) * 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (es) * 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
AU2016308624B2 (en) * 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) * 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
EP3368062A4 (fr) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la craniosynostose chez un patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (fr) * 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Traitement d'une faiblesse musculaire à l'aide de phosphatases alcalines
WO2017171871A1 (fr) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Procédés de traitement de l'hypophosphatasie chez les adolescents et les adultes
EP3436020A4 (fr) * 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
CA3026420A1 (fr) 2016-06-07 2017-12-14 Gliknik Inc. Stradomeres optimises par la cysteine
EP3474886B1 (fr) 2016-06-27 2021-08-04 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez l'enfant et l'adolescent
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
US20200317745A1 (en) * 2016-11-30 2020-10-08 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
WO2018164995A1 (fr) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Procédé de fabrication de glycoprotéine
EP3600383A4 (fr) * 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie (hpp) chez l'adulte et l'adolescent
WO2019139891A1 (fr) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Agents de phosphatase alcaline pour le traitement de troubles neurodéveloppementaux
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
EP3768302A4 (fr) 2018-03-20 2021-12-15 Synthetic Biologics, Inc. Formulations de phosphatase alcaline intestinale
EP3773686B1 (fr) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Agents au phosphatase alcaline pour le traitement de troubles dus à une exposition à des radiations
EP3773684A1 (fr) * 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Production de glycoprotéines
CN110499283A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备改善低碱性磷酸酯酶症干细胞成骨分化能力异常产品中的应用
JP2023504208A (ja) * 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
AU2021338361A1 (en) * 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
EP4291224A1 (fr) 2021-02-12 2023-12-20 Alexion Pharmaceuticals, Inc. Polypeptides de phosphatase alcaline et leurs méthodes d'utilisation
WO2024050464A2 (fr) * 2022-08-31 2024-03-07 University Of Utah Research Foundation Compositions de gja1-20 k et méthodes pour atténuer une lésion d'ischémie-reperfusion

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
CA2166118C (fr) 1993-06-24 2007-04-17 Frank L. Graham Vecteurs d'adenovirus pour therapie genique
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP1232276B8 (fr) 1999-11-16 2007-06-27 Genzyme Corporation Vecteurs et transgenes ayant des elements regulateurs pour l'administration de genes dans le foie
DE60233047D1 (de) 2001-05-14 2009-09-03 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
CA2433479A1 (fr) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugue d'un tissu alkalin-phosphatase et dextran non-specifique, methode de fabrication et utilisation
EP1759001B1 (fr) * 2004-04-21 2011-04-13 Enobia Pharma Inc. Conjugues de delivrance dans l'os et procede d'utilisation pour le ciblage de proteines vers l'os
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2006002203A2 (fr) 2004-06-23 2006-01-05 Genzyme Corporation Methodes et compositions servant au traitement de maladies polykystiques
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
MX2007006524A (es) 2004-12-01 2007-06-22 Genzyme Corp Metodos para el suministro dirigido de material genetico al higado.

Also Published As

Publication number Publication date
EP2368999A1 (fr) 2011-09-28
DK2368999T3 (da) 2014-05-26
AU2008250945A2 (en) 2009-12-24
PL2158319T3 (pl) 2012-05-31
AU2008250945B2 (en) 2013-12-12
WO2008138131A9 (fr) 2009-08-06
RS53302B (en) 2014-08-29
JP5732603B2 (ja) 2015-06-10
EP2662448A1 (fr) 2013-11-13
HUE031655T2 (hu) 2017-07-28
HK1162589A1 (en) 2012-08-31
ES2471915T3 (es) 2014-06-27
PT2368999E (pt) 2014-05-26
LTPA2016004I1 (lt) 2016-02-25
EP2158319B1 (fr) 2011-12-07
ES2619332T3 (es) 2017-06-26
EP2368999B1 (fr) 2014-03-12
BR122019000505B1 (pt) 2022-01-18
PT2158319E (pt) 2012-03-06
NL300798I2 (fr) 2016-03-16
AU2008250945A1 (en) 2008-11-20
BRPI0811198A2 (pt) 2014-10-21
EP2158319A4 (fr) 2010-07-21
BRPI0811198B8 (pt) 2021-05-25
US20100297119A1 (en) 2010-11-25
NO2016002I2 (no) 2016-02-02
BRPI0811198A8 (pt) 2018-07-31
HK1141047A1 (en) 2010-10-29
NO2016002I1 (fr) 2016-02-02
SI2368999T1 (sl) 2014-07-31
ATE536413T1 (de) 2011-12-15
PL2662448T3 (pl) 2017-07-31
EP2158319A1 (fr) 2010-03-03
CA2687001C (fr) 2019-02-12
BR122019000505A2 (pt) 2021-12-14
EP2662448B1 (fr) 2016-12-21
DE202008018131U1 (de) 2011-12-30
CY2016005I2 (el) 2016-08-31
DK2662448T3 (en) 2017-03-20
LTC2368999I2 (lt) 2017-09-25
HK1191372A1 (zh) 2014-07-25
ME01828B (me) 2014-12-20
NL300798I1 (fr) 2016-03-16
HRP20140416T1 (hr) 2014-06-20
WO2008138131A1 (fr) 2008-11-20
PT2662448T (pt) 2017-03-29
PL2158319T4 (pl) 2016-04-29
WO2008138131A4 (fr) 2008-12-31
IL202057A0 (en) 2011-08-01
CA2687001A1 (fr) 2008-11-20
CY2016005I1 (el) 2016-08-31
DK2158319T3 (da) 2012-03-19
ES2380546T3 (es) 2012-05-16
SI2662448T1 (sl) 2017-05-31
HUS1600005I1 (hu) 2016-02-29
BRPI0811198B1 (pt) 2021-03-09
JP2010526543A (ja) 2010-08-05
PL2368999T3 (pl) 2014-08-29

Similar Documents

Publication Publication Date Title
LU92976I2 (en) Asfotase alfa
RS52843B (en) THE NEW IS THE HYDROGEN SULPHATE
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
DK1817164T3 (da) Åndbare vind- og vandtætte syede genstande
EA201000327A1 (ru) Белок
IL186741A0 (en) Optical probe for delivery of light
MX347545B (es) Polipeptidos con actividad xilanasa.
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
HUP0101317A2 (hu) Módosított VIII-as faktor
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
BR0110999A (pt) Misturas de adesivos aquosos
DK2084198T3 (da) Beklædningssammensætning
SE0302103D0 (sv) Xylanases with enhanced thermophilicity and alkalophilicity
ATE458507T1 (de) Implantat mit mehrfachbeschichtung
DE602007010969D1 (de) Zytokinderivate
MY150639A (en) T cell adhesion molecule and antibody thereto
ATE467643T1 (de) Peptide mit proliferationshemmender wirkung
CY1115263T1 (el) Αλκαλικη φωσφαταση στοχευμενη στα οστα, κιτ και μεθοδοι χρησης αυτων